Separation of low versus high grade Crohn’s disease-associated small bowel carcinomas is improved by invasive front prognostic marker analysis.

Related Articles Separation of low versus high grade Crohn’s disease-associated small bowel carcinomas is improved by invasive front prognostic marker analysis. J Crohns Colitis. 2019 Aug 16;: Authors: Arpa G, Grillo F, Giuffrida P, Nesi G, Klersy C, Mescoli C, Lenti MV, Lobascio G, Martino M, Latella G, Malvi D, Macciomei MC, Fociani P, Villanacci V, Rizzo A, Ferrero S, Sessa F, Orlandi A, Monteleone G, Biancone L, Cantoro L, Tonelli F, Ciardi A, Poggioli G, Rizzello F, Ardizzone S, Sampietro G, Solina G, Oreggia B, Papi C, D’Incà R,…

Read More

Review article: the role of the autonomic nervous system in the pathogenesis and therapy of IBD.

Review article: the role of the autonomic nervous system in the pathogenesis and therapy of IBD. Aliment Pharmacol Ther. 2019 Aug 16;: Authors: Mogilevski T, Burgell R, Aziz Q, Gibson PR Abstract BACKGROUND: There is a growing body of evidence implicating a role for the brain-gut axis in the pathogenesis of inflammation in patients with IBD. AIMS: To perform a narrative review of published literature regarding the association of the autonomic nervous system and intestinal inflammation and to describe the rationale for and emerging use of autonomic manipulation as a…

Read More

Stopping 5-Aminosalicylate Therapy in Patients With Crohn’s Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes.

Stopping 5-Aminosalicylate Therapy in Patients With Crohn’s Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes. Clin Gastroenterol Hepatol. 2019 Aug 13;: Authors: Ungaro RC, Limketkai BN, Jensen CB, Yzet C, Allin KH, Agrawal M, Ullman T, Burisch J, Jess T, Colombel JF Abstract BACKGROUND & AIMS: Little is known about the effects of discontinuing 5-aminosalycilates (5-ASA) therapy for patients with Crohn’s disease (CD) who initiate therapy with an anti-tumor necrosis factor (anti-TNF) agent. We analyzed data from 2 national population cohorts to compare outcomes of patients with…

Read More

Intestinal resection rates in Crohn’s disease decline across two different epidemiological areas: a consistent observation not merely due to introduction of anti-TNFα.

Related Articles Intestinal resection rates in Crohn’s disease decline across two different epidemiological areas: a consistent observation not merely due to introduction of anti-TNFα. Gut. 2019 Aug 14;: Authors: Beelen EMJ, van der Woude CJ, de Vries AC PMID: 31413165 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31413165?dopt=Abstract

Read More

Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease-results from the ENEIDA registry. Authors’ reply.

Related Articles Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease-results from the ENEIDA registry. Authors’ reply. Aliment Pharmacol Ther. 2019 Sep;50(5):600-601 Authors: Iborra M, Beltrán B, Nos P PMID: 31414541 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31414541?dopt=Abstract

Read More

Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease-results from the ENEIDA registry.

Related Articles Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease-results from the ENEIDA registry. Aliment Pharmacol Ther. 2019 Sep;50(5):599-600 Authors: Frasca JD, Cheifetz AS PMID: 31414548 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31414548?dopt=Abstract

Read More

Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: novel therapeutic target?

Related Articles Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: novel therapeutic target? Gut. 2019 Aug 13;: Authors: Garg M, Royce SG, Tikellis C, Shallue C, Batu D, Velkoska E, Burrell LM, Patel SK, Beswick L, Jackson A, Britto K, Lukies M, Sluka P, Wardan H, Hirokawa Y, Tan CW, Faux M, Burgess AW, Hosking P, Monagle S, Thomas M, Gibson PR, Lubel J Abstract OBJECTIVE: We evaluated the influence of the renin-angiotensin system (RAS) on intestinal inflammation and fibrosis. DESIGN: Cultured human colonic myofibroblast…

Read More

Rates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated With Radiation Therapy.

Rates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated With Radiation Therapy. Inflamm Bowel Dis. 2019 Aug 14;: Authors: Feagins LA, Kim J, Chandrakumaran A, Gandle C, Naik KH, Cipher DJ, Hou JK, Yao MD, Gaidos JKJ Abstract BACKGROUND: Patients with inflammatory bowel disease (IBD) may be at higher risk for complications from radiation treatment for prostate cancer. However, available data are limited, and controversy remains regarding the best treatment approach for IBD patients who develop prostate cancer. METHODS: A retrospective cohort study across 4…

Read More
<< Go Back